William Chou
Fortune : 37 643 $ au 31/05/2026
Fortune : 37 643 $ au 31/05/2026
Dr. William Chou is a President, Chief Executive Officer & Director at Passage Bio, Inc. He is on the Board of Directors at Passage Bio, Inc. Dr. Chou was previously employed as a Chief Executive Officer by Aruvant Sciences, Inc. and a Vice President by Novartis Pharma AG.
He received his undergraduate degree from Princeton University, an MBA from Yale School of Management and a doctorate degree from the University of Pittsburgh School of Medicine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/03/2026 | 6 524 ( 0,2% ) | 37 643 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PASSAGE BIO, INC. | Directeur Général | 10/10/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Directeur Général | 01/10/2022 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01/10/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Yale School of Management
Yale School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national